[go: up one dir, main page]

CU20180001A7 - Derivados de oxopiridina sustituidos y procesos para su preparación - Google Patents

Derivados de oxopiridina sustituidos y procesos para su preparación

Info

Publication number
CU20180001A7
CU20180001A7 CUP2018000001A CU20180001A CU20180001A7 CU 20180001 A7 CU20180001 A7 CU 20180001A7 CU P2018000001 A CUP2018000001 A CU P2018000001A CU 20180001 A CU20180001 A CU 20180001A CU 20180001 A7 CU20180001 A7 CU 20180001A7
Authority
CU
Cuba
Prior art keywords
processes
preparation
derivatives
substituted
oxopiridine
Prior art date
Application number
CUP2018000001A
Other languages
English (en)
Other versions
CU24512B1 (es
Inventor
Dr Jens Ackerstaff
Dr Pascal Ellerbrock
Stefan Heitmeier
Prof Dr Alexander Hillisch
Nuñez Dr Eloisa Jimenez
Dr Dieter Lang
Dr Daniel Meibom
Dr Katharina Meier
Dr Susanne Röhrig
Dr Jan Stampfuss
Dr Adrian Tersteegen
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20180001A7 publication Critical patent/CU20180001A7/es
Publication of CU24512B1 publication Critical patent/CU24512B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

<p>La invención se refiere a derivados de oxopiridina sustituidos  de fórmula (I)</p> <p>ESPACIO PARA FÓRMULA (I)</p> <p> a procesos para su preparación. </p>
CU2018000001A 2015-07-09 2016-07-05 Derivados de oxopiridina sustituidos CU24512B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15176099 2015-07-09
EP16157350 2016-02-25
PCT/EP2016/065787 WO2017005725A1 (en) 2015-07-09 2016-07-05 Substituted oxopyridine derivatives

Publications (2)

Publication Number Publication Date
CU20180001A7 true CU20180001A7 (es) 2018-06-05
CU24512B1 CU24512B1 (es) 2021-05-12

Family

ID=56345141

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000001A CU24512B1 (es) 2015-07-09 2016-07-05 Derivados de oxopiridina sustituidos

Country Status (39)

Country Link
US (4) US10421742B2 (es)
EP (1) EP3319956B1 (es)
JP (1) JP6871180B2 (es)
KR (1) KR102596164B1 (es)
CN (2) CN108026072B (es)
AU (1) AU2016289746B2 (es)
CA (1) CA2990901C (es)
CL (1) CL2018000039A1 (es)
CO (1) CO2018000113A2 (es)
CR (1) CR20180017A (es)
CU (1) CU24512B1 (es)
CY (1) CY1123996T1 (es)
DK (1) DK3319956T3 (es)
DO (1) DOP2018000004A (es)
EA (1) EA036208B1 (es)
EC (1) ECSP18001308A (es)
ES (1) ES2856554T3 (es)
GE (1) GEP20197046B (es)
HR (1) HRP20210459T1 (es)
HU (1) HUE053552T2 (es)
IL (1) IL256556B (es)
JO (1) JO3703B1 (es)
LT (1) LT3319956T (es)
MA (1) MA42376B1 (es)
MX (1) MX377903B (es)
MY (1) MY196640A (es)
NI (1) NI201800001A (es)
PE (1) PE20180538A1 (es)
PH (1) PH12018500057A1 (es)
PL (1) PL3319956T3 (es)
RS (1) RS61584B1 (es)
SI (1) SI3319956T1 (es)
SV (1) SV2018005610A (es)
TN (1) TN2018000011A1 (es)
TW (1) TWI717367B (es)
UA (1) UA122341C2 (es)
UY (1) UY36780A (es)
WO (1) WO2017005725A1 (es)
ZA (1) ZA201800826B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2722423T3 (es) * 2014-09-24 2019-08-12 Bayer Pharma AG Derivados de oxopiridina sustituidos
EP3271332A1 (de) * 2015-03-19 2018-01-24 Bayer Pharma Aktiengesellschaft Oxopyridin-derivate als faktor xia hemmer zur behandlung von thrombose
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
CN113912586B (zh) 2016-08-31 2023-04-07 江苏恒瑞医药股份有限公司 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用
UA126940C2 (uk) * 2018-03-15 2023-02-22 Баєр Акціенгезельшафт Спосіб отримання двох похідних 4-{[(2s)-2-{4-[5-хлор-2-(4-хлор-1h-1,2,3-триазол-1-іл)феніл]-5-метоксі-2-оксопіридин-1(2h)-іл}бутаноїл]аміно}-2-фторбензаміду
BR112020018237A2 (pt) 2018-04-10 2020-12-29 Bayer Pharma Aktiengesellschaft Derivado de oxipiridina substituída
EP3822264A4 (en) 2018-07-02 2021-11-10 Jiangsu Hengrui Medicine Co., Ltd. CRYSTALLINE FORMS OF AN OXYPYRIDINE AMIDE DERIVATIVE AND THEIR PREPARATION PROCESS
AR115870A1 (es) 2018-07-31 2021-03-10 Sumitomo Chemical Co MÉTODO PARA CONTROLAR EL HONGO DE LA ROYA DE LA SOJA QUE TIENE RESISTENCIA AL INHIBIDOR DE SITIO Qₒ
EP3898611A1 (en) 2018-12-17 2021-10-27 Bayer Aktiengesellschaft Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications
SG11202104384PA (en) 2018-12-21 2021-05-28 Bayer Ag Substituted oxopyridine derivatives
EP3898634A1 (en) 2018-12-21 2021-10-27 Bayer Aktiengesellschaft Substituted oxopyridine derivatives
KR20220084301A (ko) * 2019-09-27 2022-06-21 심천 사루브리스 퍼머수티칼스 컴퍼니 리미티드 FXIa 억제제와 이의 제조 방법 및 의약 용도
EP4215525A4 (en) 2020-09-17 2024-08-21 Zhejiang Hisun Pharmaceutical Co., Ltd. Piperazine derivative, preparation method therefor and use thereof
CN114621140B (zh) * 2020-12-10 2023-08-11 中国科学院上海药物研究所 芳基二氟乙酰胺化合物及其制备方法和用途
CR20230431A (es) * 2021-03-09 2023-10-27 Bayer Ag Formas de dosificación farmacéuticas que comprenden (4S)–24–cloro–4–etil–73–fluoro–35– metoxi–32,5–dioxo–14–(trifluorometil)–32H–6–aza–3(4,1)–piridina–1(1)–[1,2,3]triazola– 2(1,2),7(1) dibencenaheptafano–74–carboxamida
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
US20240174633A1 (en) 2021-03-09 2024-05-30 Bayer Aktiengesellschaft Crystalline forms of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
CN113666826B (zh) * 2021-07-30 2024-03-26 五邑大学 一种芳基或杂芳基甲氧基化反应的方法
CN116199672A (zh) * 2021-11-30 2023-06-02 成都泰和伟业生物科技有限公司 一种嘧啶酰胺类衍生物及其制备方法和用途
WO2023174399A1 (zh) * 2022-03-18 2023-09-21 苏州晶云药物科技股份有限公司 取代的氧代吡啶类衍生物的晶型及其制备方法
CN116262735B (zh) * 2022-11-18 2025-05-13 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116262734B (zh) * 2022-11-18 2025-05-13 成都施贝康生物医药科技有限公司 氧代吡啶类化合物及其制备方法和用途
CN116262740A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116082303B (zh) 2022-12-21 2025-02-25 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其中间体和应用
CN116262736B (zh) * 2022-12-26 2025-05-13 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN120936342A (zh) 2023-03-31 2025-11-11 拜耳公司 包含(4s)-24-氯-4-乙基-73-氟-35-甲氧基-32,5-二氧代-14-(三氟甲基)-32h-6-氮杂-3(4,1)-吡啶-1(1)-[1,2,3]三唑-2(1,2),7(1)-二苯杂七蕃-74-甲酰胺的药物剂型
CN116621742B (zh) * 2023-06-09 2025-05-06 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116751136B (zh) * 2023-06-21 2025-08-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116535392B (zh) * 2023-06-26 2023-09-05 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物的制备方法及中间体和应用
WO2024251276A1 (zh) * 2023-06-09 2024-12-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体和应用
CN116621728B (zh) * 2023-06-09 2025-07-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116730861A (zh) * 2023-06-21 2023-09-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116874387B (zh) * 2023-06-21 2025-08-26 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN117164566B (zh) * 2023-09-07 2025-06-06 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117164565B (zh) * 2023-09-07 2025-05-27 成都施贝康生物医药科技有限公司 一种氧代嘧啶类化合物及其制备方法和用途
CN117164561A (zh) * 2023-09-07 2023-12-05 成都施贝康生物医药科技有限公司 一种氧代嘧啶类化合物及其制备方法和用途
CN117164564B (zh) * 2023-09-07 2025-07-08 成都施贝康生物医药科技有限公司 氧代哒嗪类化合物及其制备方法和用途
CN117164563B (zh) * 2023-09-07 2025-06-10 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途
CN117164562B (zh) * 2023-09-07 2025-06-13 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117186073B (zh) * 2023-09-08 2025-06-06 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途
CN118894814B (zh) * 2024-07-15 2025-09-12 上海康鹏科技股份有限公司 1-(2-溴-4-氯苯基)-4-(三氟甲基)-1h-1，2，3-三唑的制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
WO2002042273A2 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
EP1526131A1 (en) 2003-10-22 2005-04-27 Graffinity Pharmaceuticals Aktiengesellschaft Aminoalkyl-pyrazinones and -pyridones as thrombin inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CN101490036B (zh) 2006-05-05 2013-07-17 米伦纽姆医药公司 Xa因子抑制剂
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
CN103987696B (zh) 2011-10-14 2016-12-21 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
NO2794597T3 (es) * 2011-12-21 2018-04-14
GB2497806A (en) 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
HRP20170506T1 (hr) * 2012-08-03 2017-06-02 Bristol-Myers Squibb Company Dihidropiridon p1 kao inhibitori xia faktora
US9617259B2 (en) 2013-03-14 2017-04-11 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
WO2014160592A2 (en) * 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
JP6410819B2 (ja) 2013-07-23 2018-10-24 バイエル ファーマ アクチエンゲゼルシャフト 置換オキソピリジン誘導体および第ＸＩａ因子／血漿としてのその使用
CN105849109B (zh) * 2013-10-30 2018-01-23 拜耳制药股份公司 取代的氧代吡啶衍生物
WO2015116886A1 (en) 2014-01-31 2015-08-06 Bristol-Myers Squibb Company Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
CN105829298B (zh) 2014-02-14 2019-02-01 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
WO2016046157A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Faktor xia hemmende pyridobenzazepin- und pyridobenzazocin-derivate
US10167280B2 (en) 2014-09-24 2019-01-01 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
ES2713624T3 (es) 2014-09-24 2019-05-23 Bayer Pharma AG Derivados de oxopiridina sustituidos
ES2722423T3 (es) 2014-09-24 2019-08-12 Bayer Pharma AG Derivados de oxopiridina sustituidos
US10071995B2 (en) * 2014-09-24 2018-09-11 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
EP3197880B1 (de) 2014-09-24 2018-10-24 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
US10336730B2 (en) * 2015-08-05 2019-07-02 Bristol-Myers Squibb Company Substituted glycine derived FXIA inhibitors

Also Published As

Publication number Publication date
AU2016289746B2 (en) 2020-08-20
MA42376A (fr) 2018-05-16
JO3703B1 (ar) 2021-01-31
ZA201800826B (en) 2021-08-25
US11180471B2 (en) 2021-11-23
PL3319956T3 (pl) 2021-07-05
MX2018000076A (es) 2018-02-26
SV2018005610A (es) 2018-04-27
KR20180026761A (ko) 2018-03-13
EP3319956B1 (en) 2021-01-06
JP2018519323A (ja) 2018-07-19
HUE053552T2 (hu) 2021-07-28
CR20180017A (es) 2018-03-07
DOP2018000004A (es) 2018-01-31
MX377903B (es) 2025-03-10
EP3319956A1 (en) 2018-05-16
NI201800001A (es) 2018-10-19
UA122341C2 (uk) 2020-10-26
CL2018000039A1 (es) 2018-07-13
DK3319956T3 (da) 2021-03-29
US20180194745A1 (en) 2018-07-12
HK1255045A1 (zh) 2019-08-02
CA2990901A1 (en) 2017-01-12
EA036208B1 (ru) 2020-10-14
US20250282748A1 (en) 2025-09-11
CO2018000113A2 (es) 2018-06-12
RS61584B1 (sr) 2021-04-29
US10421742B2 (en) 2019-09-24
WO2017005725A1 (en) 2017-01-12
US20190367478A1 (en) 2019-12-05
HRP20210459T1 (hr) 2021-05-14
UY36780A (es) 2017-01-31
CN113292539B (zh) 2023-12-22
TWI717367B (zh) 2021-02-01
PE20180538A1 (es) 2018-03-20
BR112018000209A2 (pt) 2018-09-04
SI3319956T1 (sl) 2021-02-26
MY196640A (en) 2023-04-25
PH12018500057A1 (en) 2018-07-09
KR102596164B1 (ko) 2023-11-01
GEP20197046B (en) 2019-12-10
AU2016289746A1 (en) 2018-01-25
IL256556A (en) 2018-02-28
MA42376B1 (fr) 2021-04-30
US20230024752A1 (en) 2023-01-26
CU24512B1 (es) 2021-05-12
CN108026072A (zh) 2018-05-11
CA2990901C (en) 2024-11-12
CN113292539A (zh) 2021-08-24
CN108026072B (zh) 2021-08-17
EA201890111A1 (ru) 2018-06-29
ES2856554T3 (es) 2021-09-27
TW201706261A (zh) 2017-02-16
TN2018000011A1 (en) 2019-07-08
JP6871180B2 (ja) 2021-05-12
LT3319956T (lt) 2021-02-10
ECSP18001308A (es) 2018-03-31
CY1123996T1 (el) 2022-07-22
IL256556B (en) 2021-02-28
NZ739109A (en) 2024-09-27

Similar Documents

Publication Publication Date Title
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
AR132627A2 (es) Procesos para preparar compuestos intermediarios de utilidad para sintetizar compuestos de carbamoilpiridona policíclicos
MX2018006148A (es) Inhibidores de cxcr2.
DOP2017000176A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
MX2018003130A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas a receptor de interleucina-1 (irak) y usos de los mismos.
EP3509581A4 (en) FORMULATIONS OF (R
EA201792021A1 (ru) Ингибитор jak
UY36499A (es) Uso de picolinamidas como fungicidas
EA201692219A1 (ru) Способы получения противовирусных соединений
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
MX373320B (es) Compuestos inhibidores de pde2.
PT3457851T (pt) Derivados de sobetiroma
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
HUE049606T2 (hu) Eljárás flavonoid inklúziós vegyületek elõállítására
MX2018007219A (es) Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol.
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида
HUE054815T2 (hu) 3,5-Difenil-diazol vegyületek vízoldható származékai
CL2017000151A1 (es) Derivados de piridona
EP3277701A4 (en) SYNTHESIS OF DESOSAMINES
CL2017002255A1 (es) Procesos para preparar fluorocetólidos.
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης